Jenny Iversen1, Jason Grebely2, Beth Catlett3, Philip Cunningham3, Gregory J Dore2, Lisa Maher2. 1. The Kirby Institute, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: jiversen@kirby.unsw.edu.au. 2. The Kirby Institute, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2052, Australia. 3. St Vincent's Centre for Applied Medical Research, Sydney, Australia.
Abstract
BACKGROUND: Hepatitis C virus (HCV) infection is endemic among people who inject drugs (PWID) globally. Despite high prevalence, treatment uptake is low, with cumulative uptake <10% in most settings. This study aimed to populate the cascade of HCV testing, care and treatment among PWID using data collected in Australia prior to the introduction of broadly accessible interferon-free direct-acting antiviral (DAA) therapies in March 2016. METHODS: The Australian Needle and Syringe Program Survey is a cross-sectional surveillance system that recruits ∼2300 PWID annually and collects behavioural data and dried blood samples (DBS). HCV antibody and ribonucleic acid (RNA) test results from DBS collected in 2015 were combined with data on HCV diagnostic testing, care and treatment to populate the HCV cascade among Australian PWID. RESULTS: Among an estimated 93,000 PWID in Australia in 2015, the majority (89%) had a lifetime history of HCV antibody testing. More than half (57%) of PWID tested HCV antibody positive and of these, 79% had detectable HCV RNA consistent with active infection. Less than half (46%) of HCV antibody positive PWID had received confirmatory HCV RNA testing. Among the estimated 43,201 PWID with active infection or chronic infection that had been successfully treated, 31% had received specialist HCV assessment, 8% had received antiviral treatment and 3% were cured. CONCLUSION: This study provides baseline estimates of the cascade of HCV testing, care and treatment among PWID through enhancement of a well-established surveillance mechanism. Characterisation of the HCV cascade among PWID will be crucial to evaluating and monitoring the roll out of direct-acting antiviral therapies in Australia, including assessing potential HCV treatment as prevention benefits.
BACKGROUND:Hepatitis C virus (HCV) infection is endemic among people who inject drugs (PWID) globally. Despite high prevalence, treatment uptake is low, with cumulative uptake <10% in most settings. This study aimed to populate the cascade of HCV testing, care and treatment among PWID using data collected in Australia prior to the introduction of broadly accessible interferon-free direct-acting antiviral (DAA) therapies in March 2016. METHODS: The Australian Needle and Syringe Program Survey is a cross-sectional surveillance system that recruits ∼2300 PWID annually and collects behavioural data and dried blood samples (DBS). HCV antibody and ribonucleic acid (RNA) test results from DBS collected in 2015 were combined with data on HCV diagnostic testing, care and treatment to populate the HCV cascade among Australian PWID. RESULTS: Among an estimated 93,000 PWID in Australia in 2015, the majority (89%) had a lifetime history of HCV antibody testing. More than half (57%) of PWID tested HCV antibody positive and of these, 79% had detectable HCV RNA consistent with active infection. Less than half (46%) of HCV antibody positive PWID had received confirmatory HCV RNA testing. Among the estimated 43,201 PWID with active infection or chronic infection that had been successfully treated, 31% had received specialist HCV assessment, 8% had received antiviral treatment and 3% were cured. CONCLUSION: This study provides baseline estimates of the cascade of HCV testing, care and treatment among PWID through enhancement of a well-established surveillance mechanism. Characterisation of the HCV cascade among PWID will be crucial to evaluating and monitoring the roll out of direct-acting antiviral therapies in Australia, including assessing potential HCV treatment as prevention benefits.
Authors: Conar R O'Neil; Emily Buss; Sabrina Plitt; Mariam Osman; Carla S Coffin; Carmen L Charlton; Stephen Shafran Journal: Can J Public Health Date: 2019-06-20
Authors: Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta Journal: J Subst Abuse Treat Date: 2019-01-30
Authors: Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta Journal: Int J Drug Policy Date: 2018-04-19
Authors: Judith I Tsui; Claire M Miller; John D Scott; Maria A Corcorran; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2018-12-26 Impact factor: 4.492
Authors: Lauren White; Ali Azzam; Lauren Burrage; Clare Orme; Barbara Kay; Sarah Higgins; Simone Kaye; Andrew Sloss; Jennifer Broom; Nicola Weston; Jonathan Mitchell; James O'Beirne Journal: Frontline Gastroenterol Date: 2018-10-24
Authors: Kathleen M Ward; Sean D McCormick; Mark Sulkowski; Carl Latkin; Geetanjali Chander; Oluwaseun Falade-Nwulia Journal: Int J Drug Policy Date: 2020-11-04